Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Evidence synthesis

Draft safety review: the rodent thyroid C-cell signal and its human relevance

Consultation on the draft safety review of the rodent thyroid C-cell signal observed with glucagon-like peptide-1 receptor agonists and its relevance to humans. The review assesses the mechanistic evidence for a species difference in C-cell receptor…

Document identifier
CEI-CP-019
Series
Public comment period
Version
1.0
Published
13 Jun 2025
Last reviewed
13 Jun 2025
Next review
13 Jun 2026
Identifier
10.71829/cei.cp.19
Certainty
Not rated
Cycle
2025 Q2
Window
20 Apr 2025 – 20 May 2025
Status
Closed
Submissions
16

§1Consultation and window

§1.1Window

Opened
20 April 2025
Closed
20 May 2025
Duration
30 days
Status
Closed — the disposition is published
Document under consultation
Synthesis: The rodent thyroid C-cell signal and its human relevance
Submissions received
16

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the treatment of the rodent finding proportionate, given that it drives a contraindication carried in labelling across the class?
  2. Is the human evidence, which is drawn from registries and pharmacovigilance databases rather than from trials, characterised correctly as to what it can and cannot establish?
  3. Should the review state a conclusion on human relevance at all, given the certainty it assigns?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The review was amended before ratification. It states that the human relevance of the rodent signal is not established rather than that it is absent, a distinction several respondents pressed, and the registry evidence is now reported with its detection limits stated.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.